Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial - Wikidata - awgldk - TriplyDB

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial

http://www.wikidata.org/entity/Q34674697

about

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial.Recombinant Human Growth Hormone: HIV-Related Lipodystrophy.

P2860

Q35186541-93CF2E8D-1299-4EE2-A238-D66C8B91D282 Q37085712-778D0FEF-13B6-48CB-A305-FC6D9C078BD3 Q37415273-27B52D2F-FAE9-4BCE-999E-B969EFA32CC5 Q40864476-6000A96E-E884-4072-806A-4ECF95C09885

P2860

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial

http://www.wikidata.org/entity/Q34674697

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Recombinant human growth hormo ...... bo-controlled, factorial trial

@ast

Recombinant human growth hormo ...... bo-controlled, factorial trial

@en

Recombinant human growth hormo ...... bo-controlled, factorial trial

@nl

type

label

Recombinant human growth hormo ...... bo-controlled, factorial trial

@ast

Recombinant human growth hormo ...... bo-controlled, factorial trial

@en

Recombinant human growth hormo ...... bo-controlled, factorial trial

@nl

prefLabel

Recombinant human growth hormo ...... bo-controlled, factorial trial

@ast

Recombinant human growth hormo ...... bo-controlled, factorial trial

@en

Recombinant human growth hormo ...... bo-controlled, factorial trial

@nl

P1433

Q34674697-F62786EC-D76B-4F64-92F6-C6CA545717F2

P1476

Q34674697-A14D3FDE-AFB0-4119-9315-F3A3CA3DA45B

P2093

Q34674697-0F7FEFCC-3235-47D3-8816-0D65B462E35A

Q34674697-2CAC5C9B-83CF-47B2-8E43-F510457C71F9

Q34674697-340EC0C5-E6F4-451B-9A27-FB4C80A408AA

Q34674697-3FCD7A93-4AB8-44CD-B859-A0C83DF20A0E

Q34674697-4BA1C149-4DB1-4D91-BD6A-A0EBC85C2109

Q34674697-4C77042C-E519-4417-8CEE-D4F8DDE9270C

Q34674697-78B47C3D-3357-46AA-BE85-449C282A9F7E

Q34674697-837CB051-CABA-4750-838F-C8DA97EA36BA

Q34674697-A58C14AF-B899-44AB-9387-D9F64CD80309

Q34674697-B0D1699D-CEFB-4C39-9F60-3309CDA867F2

P2860

Q34674697-03A25874-8762-4F94-A290-01A8C6B47CA4

Q34674697-0A5B1D05-8CBD-46BD-A204-16D40FD3637D

Q34674697-0B93FCF2-C7C5-4734-89BA-3269D017AD94

Q34674697-16239DA2-3E94-40FC-A8AC-70937CCF7707

Q34674697-1A66500C-237B-4546-9A12-8356DDBDABF5

Q34674697-1FD23DCB-AD8A-4E26-A11F-9179FB328A02

Q34674697-23894283-E182-47DC-8AEE-FFD47BFC7CB1

Q34674697-23B67821-DEAC-4013-89EA-E00ADBCCF230

Q34674697-285413A8-9AEF-4C01-AA67-D50C2CE53493

Q34674697-36516B28-AF84-4689-BA07-E9AEBC46B7D6

P304

Q34674697-915BA477-233B-4CA1-B85A-6A0798BFFF9F

P31

Q34674697-D8CD878D-B682-4147-85A1-ED6B3924703D

P356

Q34674697-9BD6E2D4-2EE5-4C99-B7CD-6CB0034C4B90

P407

Q34674697-8636A0EC-95DA-4ECC-B9EF-85ECB8DB2EEF

P433

Q34674697-A3E2EFA3-2B2C-41F0-B2D9-76981FD38FE0

P478

Q34674697-0854DF6A-EA05-4536-9AB9-74711846F2EF

P577

Q34674697-488F2014-4CD4-4DB1-9798-BC7992225090

P5875

Q34674697-3D9006A6-CD0E-48AA-8B87-8B48AEDEB2D4

P698

Q34674697-77BED527-F697-46E1-AADE-36AB84775CEF

P921

Q34674697-F6815EDE-A69F-41E4-B6F2-EEA4F649E7C2

P932

Q34674697-359100D2-0267-4844-86B9-D1AC5A195F54

P356

JOURNAL.PONE.0061160

P1433

P1476

Recombinant human growth hormo ...... bo-controlled, factorial trial

@en

P2093

Daniel Donovan

http://www.w3.org/2001/XMLSchema#string

Donald P Kotler

http://www.w3.org/2001/XMLSchema#string

Ellen Engelson

http://www.w3.org/2001/XMLSchema#string

Henry N Ginsberg

http://www.w3.org/2001/XMLSchema#string

Jeanine Albu

http://www.w3.org/2001/XMLSchema#string

Jerry Ernst

http://www.w3.org/2001/XMLSchema#string

Kirsis Ham

http://www.w3.org/2001/XMLSchema#string

Marshall J Glesby

http://www.w3.org/2001/XMLSchema#string

Martin Lesser

http://www.w3.org/2001/XMLSchema#string

Qing He

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial

Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.

The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy.

P304

e61160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0061160

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236207787

http://www.w3.org/2001/XMLSchema#string

P698

23593417

http://www.w3.org/2001/XMLSchema#string

P921

P932

3625151

http://www.w3.org/2001/XMLSchema#string